Pilatus Biosciences was founded in 2022 by two Taiwanese co-founders, Professor Ping-Chih Ho of the University of Lausanne and pharmaceutical expert Dr. Yun-Han Lin, and is dedicated to the research and development of first-in-class biologics targeting metabolic checkpoints to advance the development of cancer immunotherapy. Pilatus Biosciences conducts cutting-edge research at the Biopôle campus in Epalinges, Switzerland, and manages strategic collaborations and project development through its subsidiary located in the Taipei Bioinnovation Park.

The founders and core team have deeply cultivated expertise in innovative drug development and business development for many years. The company has established a drug R&D platform to integrate external R&D capabilities and rapidly advance research and development. In terms of scientific innovation, patent layout, and business cooperation, the company is progressively strengthening high-value business development and licensing (BD&L) opportunities, and does not rule out a future exit model through international pharmaceutical mergers and acquisitions (M&A) at the hundred-million-dollar level. Since its incorporation in the United States in November 2022, the company has actively collaborated with leading global research institutions and medical centers to conduct preclinical drug development and translational medicine research. In July 2024, it established an ex-vivo patient sample culture platform in Taiwan to conduct clinical biomarker research for PLT012, supporting the initiation of Phase I clinical human trials in Taiwan and the United States in 2025. The company hopes to drive progress in the field of disease treatment through continuous innovation, providing more effective and safer treatment options for medical needs.